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Available online xxxxNeurological manifestations are potentially associated with hepatitis E virus (HEV) infection in Europe, mainly
attributed to genotype (GT) 3 HEV infection. In this study, we determined the frequency and causal relationship
of HEV in patientswith non-traumatic neurological disorders in China,where GT4HEV is prevalent. 1117 consec-
utive patients diagnosedwith neurological illnesses in a hospital of eastern China and 1475 healthy controls who
took routine examination in the samehospitalwere tested for HEV by serology andmolecularmethods. Anti-HEV
IgM antibodies were detectable in 6 (0.54%) of the patients and 10 (0.68%) of the healthy controls (P=0.651).
Serum HEV RNA was detected in all of the 16 individuals with positive anti-HEV IgM. The six patients with
HEV infection included two viral encephalitis, two posterior circulation ischemia, one peripheral neuropathy
and one Guillian-Barré syndrome. They had no symptoms of acute viral hepatitis except two patients of viral en-
cephalitis that showed mildly transaminitis. Additional, 39.51% patients and 35.63% controls without acute HEV
infection were positive for anti-HEV IgG (P=0.144). Anti-HEV IgG positivity was more frequent in male and el-
derly in both the patients and control groups, but unrelated to the incidence of any non-traumatic neurological
illness, hospital stay or treatment outcome, except linking to better outcome of hemorrhagic stroke disease.
These data demonstrated that HEV appears not to contribute to acute neurological disorders in China. Neverthe-
less, we cannot exclude a possible causative role, suggesting that testing HEV in this population, especially in sit-
uations of unexplained deregulated liver function would be warranted.
© 2018 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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10.1016/j.ebiom.2018.08.053identiﬁed. Genotype (GT) 1 andGT2HEV are restricted to human beings
and transmitted via contaminatedwater sources, which are prevalent in
developing countries. GT3 and GT4 HEV are zoonotic and commonly
spread through consumption of undercooked pork or game products,
which are endemic in both developing and developed countries [2]. Al-
though HEV infection is asymptomatic in approximately 95% cases, it
may result in wide-range clinical events, including hepatitis, acute pan-
creatitis, renal injury, neurological disorders and other immune-
mediated manifestations [3–6].
As the most common extra-hepatic complication, N150 cases of
HEV-associated neurological syndromes have been reported in devel-
oping and developed countries, mostly as case reports or small cohort
series. Themost frequently reportedHEV-related neurologic syndromes
include Guillain–Barré syndrome (GBS), neuralgic amyotrophy (NA),er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
non-traumatic neuropathy: A large prospective case-control study in
Research in context
Evidence before this study
Although hepatitis E virus (HEV) infection is asymptomatic in ap-
proximately 95% cases, it may result in wide-range clinical
events, and neurological injury is the most common extra-
hepatic manifestation in patients with HEV infection. N150
cases of HEV-associated neurological syndromes have been re-
ported in developing and developed countries, mostly as case re-
ports or small cohort series and mainly attributed to genotype
(GT) 3 HEV infection. China is considered anHEV-endemic region,
where GT4 is prevalent. However, the roles of GT4 HEV in neuro-
logic diseases remain largely unknown due to lack of large case-
control cohort study in endemic area.
Added value of this study
The current study is the first large case-control cohort study to in-
vestigate the association of HEV infection with acute non-
traumatic neurological diseases in China, where GT4 HEV is pre-
dominant. In this study, six of 1117 (0.54%) non-traumatic neu-
ropathy injury patients and ten of 1475 (0.68%) controls had
evidence of HEV infection (P=0 .651). This result is in contrast
to all the cohort studies performed in Europe that the prevalence
of HEV viraemia in neurological patients are at least 10 times
higher than that documented in local blood donors. The six pa-
tients with HEV infection included two viral encephalitis, two pos-
terior circulation ischemia, one peripheral neuropathy and one
Guillian-Barré syndrome. They had no symptoms of acute viral
hepatitis except two patients of viral encephalitis that showed
mildly transaminitis. Anti-HEV IgG positivity was more frequent
in male and elderly in both the patients and control groups, but un-
related to the incidence of any non-traumatic neurological illness,
hospital stay or treatment outcome, except linking to better out-
come of hemorrhagic stroke disease.
Implications of all the available evidence
These data demonstrated that HEV appears not to contribute to
acute neurological disorders in China. Nevertheless, we cannot
exclude a possible causative role, suggesting that testing HEV in
this population, especially in situations of unexplainedderegulated
liver function would be warranted.
2 Y. Wang et al. / EBioMedicine xxx (xxxx) xxx–xxxencephalitis/myelitis, central nervous system (CNS) infection,
mononeuritis multiplex and Bell palsy [6]. The relationship between
HEV andother neurological diseaseswere also documentedbut the cau-
sality is less clear. The prevalence of HEV related neurological illness
vary between 2.4% to 11% from different cohort studies based on UK,
France, Netherlands, and Bangladesh [7–10]. This is much higher than
that reported in general population in the same countries. Most of
these cohort studies were performed in dedicated neurological popula-
tions, such asGBSor NA. There is only one cohort study evaluating in full
range of neurological diseases, which demonstrated a likely causal asso-
ciation as well [9].
Cases of HEV-associated neurological injury have been mainly re-
ported in Europe and Asia, where GT3 and GT1 HEV are predominant,
respectively [2,11]. To date, only two small cohort studies from China,
where GT4 HEV is predominant, have found a possible link of myasthe-
nia gravis (MG), but not GBS/encephalitis, to HEV infection [12,13].
Thus, the roles of GT4 HEV in neurologic diseases remain largelyPlease cite this article as: Wang Y, et al, Hepatitis E virus infection in acute
China, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.08.053unknown due to lack of large case-control cohort study in endemic
area. China is considered an HEV-endemic region where approximately
1.09% of acute HEV infection with detectable anti-HEV immunoglobulin
(Ig) M has been reported in blood donors [14]. In this study, we per-
formed a large prospective cohort study to determine the frequency of
HEV-associated neurological injury in Chinese patients with full range
of non-traumatic neurological disorders, as compared with healthy
controls.2. Patients and methods
2.1. Patients and controls
From September through November 2017, consecutive patients
diagnosed with acute non-traumatic neurological illnesses in the First
People's Hospital of Yancheng City, Jiangsu Province, China, were en-
rolled in the study. All patients were evaluated andmanaged by experi-
enced clinical neurologists. Serum samples were obtained onset of
diagnosis in the acute phase of disease before treatment. Serums from
consecutive individuals visiting the physical examination center of this
hospital within the same period for routine examination were collected
as healthy controls. All samples were stored at−80 °C before testing.2.2. Ethics
The standard protocol, ethical approvals and registrations of this
study were approved by ethical standards committee of The First
People's Hospital of Yancheng City and all patients provided informed
consent that allow future testing of archived bio-samples. The protocol
number of the study is [2018]-(K020).2.3. HEV serological test
All serum samples were tested for the presence of anti-HEV IgM and
IgG antibodies using commercially availableHEV ELISAKit (Wantai, Bei-
jing, China) according to manufacturer's instructions. Samples with
signal-to-noise ratio (S/N ratio) N 1.0 were considered positive.2.4. HEV molecular test
Serums with positive anti-HEV IgM were subjected to HEV RNA
detection and identiﬁcation. Total RNA was extracted using QIAamp
Viral RNAMini Kit (QIAGEN, Germany) according to themanufacturer's
instruction. Next, total RNAwas tested for HEV RNA bymeans of a Diag-
nostic Kit for Hepatitis E Virus RNA (Jinhao, Beijing, China) according to
themanufacturer's instruction. Speciﬁcally, according to the principle of
real-time ﬂuorescence quantitative polymerase chain reaction (qPCR)
detection, the conserved region of open reading frame (ORF) 3 was
identiﬁed by HEV-speciﬁc Taqman probe. The viral load of each sample
was estimated by qPCR according to series diluted artiﬁcial pseudovirus
as standards. For genotype identiﬁcation, nest-PCR was performed to
produce a 348-nucleotide amplicon from HEV ORF2 for sequencing as
previously described [15].2.5. Statistical analysis
Differences in proportions were tested using Chi-squared or Fisher
exact test; differences in continuous variables of normal distribution
were tested using the Student's t-test, and the data with skewed distri-
bution were compared using theMann-Whitney U test. Logistic regres-
sionwas performed to determine odds ratios (ORs). A two-sided P value
b0.05 was considered to be statistically signiﬁcant. Statistical analysis
was performed using SPSS version 23.0.non-traumatic neuropathy: A large prospective case-control study in
Y. Wang et al. / EBioMedicine xxx (xxxx) xxx–xxx3. Result
3.1. Study population
Between September and November 2017, 1117 patients including
626 men and 491 women were diagnosed with acute non-traumatic
neurological injury and enrolled in this study. The mean age was 67
years (range 14–94 years). The wide range of neurological illnesses
were divided into different clinical categories based on onset position
and pathogenesis. Detailed categories were summarized in Table 1.
1475 healthy controls were enrolled, including 1005 men and 470
women with the mean age of 41 years (range 0–95 years).3.2. HEV infection in patients with neurological injury
Anti-HEV IgM antibodies were positive in 6 (0.54%) of the non-
traumatic neuropathy injury patients, compared with 10 (0.68%) of
the healthy controls (Fig. 1, Table 2). The OR after adjustment for age
and sex showed a similar result (Table 2). The incidence of HEV infec-
tion and S/N ratio of positive anti-HEV IgM showed no signiﬁcant differ-
ence between cases and controls (Fig. 2). HEV RNAwas detected in all of
the 16 subjects with positive anti-HEV IgM, and the viral loads ranged
from 3.68 × 103 to 2.58 × 105 copies/mL. One sample with the highest
viral load was successfully sequenced and conﬁrmed as GT4 strain. All
the 6 patients and six out of 10 health controls with HEV infection
were also showed positive anti-HEV IgG.3.3. Neurological presentations
The mean age of the 6 neurological patients with HEV infection was
53 years (range 27–86 years) compared to 65 years (range 14–94
years) in the remaining 1111 patients with negative anti-HEV IgM (P
= 0.038). Of the six patients that had evidence of HEV infection, two
had viral encephalitis, two had posterior circulation ischemia, one had
peripheral neuropathy and one hadGBS. None of the patients presented
with jaundice. Only two patients with viral encephalitis presented with
a modestly raised alanine aminotransferase (ALT) level. Five patients
were eventually recovered from neurological syndrome. Only one pa-
tient was well-followed up and found symptoms relief along with
HEV IgM seronegative conversation. An overview of the clinical charac-
teristics and therapeutic regimens of the 6 patients with HEV infection
was summarized in Table 3, and speciﬁc descriptions are as below.3.3.1. Case 1
A 46-year-old woman had undergone surgery to remove a mam-
mary gland ﬁbroma 6 month previously. The patient presented with a
5-day history of fever associated with headache and nausea. Initial
treatment with mannitol, cefuroxime, ribavirin, and dexamethasone
was unsuccessful. Her limbs had a Medical Research Council (MRC)
score of 5, and her tendon reﬂexes were normal. Liver function tests
(LFTs) showed slightly elevated serum ALT and aspartate aminotrans-
ferase (AST). Routine blood examination showed an increased level of
C-reactive protein (CRP), implying an acute inﬂammatory reaction.
Magnetic resonance imaging (MRI) of the brain revealed abnormal
strengthening signals in the bilateral hippocampal region. The color of
the cerebrospinal ﬂuid (CSF) was transparent without bacteria, and
the levels of glucose and chloridewere normal with signiﬁcant increase
of monocytes. The ﬁnal diagnosis was viral encephalitis based on an ex-
amination of the CSF. Tests for hepatitis C virus (HCV) and herpes sim-
plex virus (HSV) were negative. The patient received antiviral
treatment with ganciclovir. She was also administered piracetam to
protect her nerves and glutathione to improve liver function. Her neuro-
logical symptoms and signs partially improved after treatment.Please cite this article as: Wang Y, et al, Hepatitis E virus infection in acute
China, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.08.0533.3.2. Case 2
A 42-year-old woman presented with a 2-month history of numb-
ness in her left upper extremities without apparent cause. Physical ex-
amination showed that the patient was anicteric and that she had
normal superﬁcial lymph nodes and tendon reﬂexes. Serological testing
showed slightly increased levels of γ-glutamyltranspeptidase (GGT)
anduric acid. CerebralMRI revealedpoint ischemia nidus in the pallium.
However, medullar MRI found no obvious abnormality in the cervical
brachial plexus nerve. Electromyography showed normal peripheral
nerves throughout the body. The cervical vertebrae C4/5 and C5/6
showed intervertebral disc herniation, while C3/4 showed interverte-
bral disc bulging. Neither Brudzinski's sign nor Murphy's sign were
present. The patient's limbs had an MRC score of 5. Final diagnosis
was peripheral neuropathy that caused by spinal degeneration. The
symptom of numbness gradually improved without treatment, and
the patient showed seronegative conversion of anti-HEV IgM after 1
week.
3.3.3. Case 3
An 87-year-old man presented with 1 month history of intermittent
dizziness repeatedly. Physical examination revealed that he was
anicteric, that he had no hemorrhage dots in the systemic skin, and
that his superﬁcial lymph nodes were normal. LFTs showed normal
serum ALT and AST, with a slightly elevated total bilirubin (TBil). The
serum level of uric acid was increased and the tendon reﬂexes were
maintained. B-ultrasonography showed sclerosiswith plaque formation
at several sites in the bilateral carotid arteries and in the intervertebral
disc section of the vertebral artery, as well as blood supply shortage to
the right side of the vertebral artery and left carotid artery. Brain com-
puted tomography showed lacunar infarction in the basal ganglia, and
the ﬁnal diagnosis was posterior circulation ischemia. The patient was
treated with alprostadil and vinpocetine to improve blood circulation,
and his symptoms of dizziness resolved after treatment.
3.3.4. Case 4
A 42-year-old man presented with sense of rotation, nausea and
vomiting, as well as aggravating dizziness. However, tinnitus and deaf-
nesswere not present. The patient had previously experienced the same
symptoms repeatedly for 2 months. Cerebral MRI showed point ische-
mia nidus in the bilateral centrum semiovale. The patient's limbs had
an MRC score of 5 and the tendon reﬂexes were normal. Both LFTs
and routine blood examination showed normal parameters. There
were no pathological signs in either limb, and deep/shallow feelings
were symmetrical. The patientwas diagnosedwith posterior circulation
ischemia and treated with gastrodin and vinpocetine to improve blood
circulation. He recovered after treatment.
3.3.5. Case 5
A 27-year-old man presented with headache that had lasted N10
days, after which it was accompanied by blurred vision. His symptoms
improved when mannitol and dexamethasone were administered, but
relapsed when treatment were withdrawn. The patient had a history
of hypertension, but had not used his medications as directed. His
serum ALT and GGT were mildly increased, while those of AST and
TBil were normal, as well as his level of CRP. CerebralMRI showed bilat-
eral ventricular point ischemia nidus. Cervical vertebra MRI revealed
physiological curvature and herniated disk at 4/5, 5/6 and 6/7. The
abducens nerve was mildly limited on both sides, and an electrocardio-
gram (ECG) indicated T wave change and sinus rhythm. The CSF was
transparent, but contained mildly elevated numbers of monocytes that
had normalized after 3 weeks. Tests for hepatitis B virus (HBV), HCV,
human immunodeﬁciency virus (HIV), HSV and treponema pallidum
(TP) were all negative. Thus, the overall clinical picture suggested viral
encephalitis, and the patient recovered after antiviral treatment with
ganciclovir. He was also administered oxiracetam to protect the nerves.non-traumatic neuropathy: A large prospective case-control study in
Table 1
Patients with neurological event tested for HEV.
Median age (range) 67 (14–94 years)
Sex (male: female) 626:491
Type of acute neurological event Number Tested(n=) Anti-IgM positive number (%)
Ischemia stroke Vertebrobasilar insufﬁciency 191 0 (0%)
Posterior circulation ischemia 145 2 (1.38%)
Transient ischaemic attack 22 0 (0%)
Cerebral venous sinus thrombosis 2 0 (0%)
Ischemia stroke 15 0 (0%)
Hemorrhagic cerebral infarction 6 0 (0%)
Massive hemispheric infarction 9 0 (0%)
Brainstem infarction 5 0 (0%)
Multiple infarction 2 0 (0%)
Cerebral infarction 225 0 (0%)
Cerebellar infarction 5 0 (0%)
Lacunar infarction 7 0 (0%)
Basal ganglia infarction 1 0 (0%)
Hemorrhagic stroke Subdural hemorrhage 1 0 (0%)
Hypertension ventricular hemorrhage 1 0 (0%)
Basal ganglia hemorrhage 18 0 (0%)
Cerebral hemorrhage 14 0 (0%)
Brainstem hemorrhage 12 0 (0%)
Intracranial hemorrhage 33 0 (0%)
Cerebellar hemorrhage 7 0 (0%)
Thalamic hemorrhage 6 0 (0%)
lobar hemorrhage 5 0 (0%)
Subaraclmoid hemorrhage 30 0 (0%)
Intraventricular hemorrhage 4 0 (0%)
Posterior circulation hemorrhage 4 0 (0%)
hemorrhagic stroke 5 0 (0%)
Neurodegenerative disease Guillain-Barre syndrome 3 1 (33.3%)
Alzheimer disease 2 0 (0%)
Myasthenia 6 0 (0%)
Peripheral neuropathy 12 1 (8.33%)
Ischialgia 3 0 (0%)
Neuralgia 1 0 (0%)
Migraine/headaches 32 0 (0%)
Dementia 2 0 (0%)
Dizziness/vertigo 28 0 (0%)
Parkinson's disease 22 0 (0%)
Neurosis 13 0 (0%)
Cranial/facial nerve palsies 7 0 (0%)
Dyssomnia 3 0 (0%)
Epilepsy 8 0 (0%)
Convulsions 3 0 (0%)
limbs numbness 2 0 (0%)
Myelopathy 5 0 (0%)
Multiple system atrophy 2 0 (0%)
Trigeminal Nerve Diseases 1 0 (0%)
Oculomotor nerve injury 2 0 (0%)
Hashimoto encephalopathy 1 0 (0%)
Paraeoplastic syndrome 1 0 (0%)
Hepatolenticular degeneration 1 0 (0%)
Sensorineural deafness 1 0 (0%)
Excessive shock response 1 0 (0%)
Hunter's syndrome 1 0 (0%)
Leukoencephalopathy 1 0 (0%)
Subacute associated lesions 1 0 (0%)
Central nervous system infections Unknown encephalitis 2 0 (0%)
Toxicencephalitis 1 0 (0%)
Viral encephalitis 26 2 (7.69%)
Myelitis 3 0 (0%)
Bacterial encephalitis 8 0 (0%)
Toxic encephalopathy 2 0 (0%)
Others Subdural haematoma 3 0 (0%)
Sequelae of cerebral infarction 57 0 (0%)
Sequela of cerebral hemorrhage 8 0 (0%)
Sequelae of cerebral apoplexy 4 0 (0%)
Brain post-traumatic syndrome 7 0 (0%)
Acute cerebrovascular disease 5 0 (0%)
Intracranial space occupying lesion 3 0 (0%)
Vertebro-basilar artery syndrome 2 0 (0%)
Arterial aneurysm 6 0 (0%)
Arteriosclerotic encephalopathy 5 0 (0%)
Focal cerebral ischemia 2 0 (0%)
Othera 33 0 (0%)
a Other: rare diseases and unknown cause.
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Fig. 1. Flowchart of patients and healthy controls at enrollment.
Table 2
Frequency of anti-HEV IgM and IgG antibodies in patients with neurological injury and healthy controls.
Neurological injury
(n= 1117)
Healthy controls
(n= 1475)
OR (95% CI) P value Adjusted OR (95% CI) Adjusted P value
Anti-HEV IgM positive 6 (0.54) 10 (0.68) 0.791 (0.287–2.183) 0.651 1.396 (0.429–4.544) 0.579
Anti-HEV IgG positive 439 (39.51) 522 (35.63) 1.180 (1.005–1.864) 0.044 0.861 (0.705–1.053) 0.144
Y. Wang et al. / EBioMedicine xxx (xxxx) xxx–xxx3.3.6. Case 6
A 71-year-old man presented with weakness of the left limb associ-
ated with slurred speech 3 days prior. He was initially admitted to the
intensive care unit with a diagnosis of severe hypokalaemia and was
then transferred to the neurology department when his symptoms
had improved. He had previously undergone a gastric perforation oper-
ation. Physical examination revealed that the patient was anicteric, that
he had no hemorrhage dot in the systemic skin, and that his superﬁcialFig. 2. Anti-HEV IgM and IgG S/N ratios for patients with neurological injury and healthy contr
represent the cutoff ratio (1.0). The P values are calculated by t-test comparing S/N ratio of posit
tation of the references to color in this ﬁgure legend, the reader is referred to the web version
Please cite this article as: Wang Y, et al, Hepatitis E virus infection in acute
China, EBioMedicine (2018), https://doi.org/10.1016/j.ebiom.2018.08.053lymph nodes were normal. Furthermore, he maintained deep tendon
reﬂexes. The patient's serum levels of ALT and AST were normal, and
his TBil was slightly elevated. His left and right limbs had MRC scores
of 4 and 5, respectively. His CSF was transparent, but contained signiﬁ-
cantly elevated levels of monocytes, glucose, and CSF protein. Chloride
level of was normal. The result of the Pany test was positive, conﬁrming
the increased levels of CSF protein. The overall clinical picture suggestedols. S/N ratios of in subjects with positive anti-HEV IgM (A) and IgG (B). Red dotted lines
ives. HEV= hepatitis E virus; Ig= immunoglobulin; S/N= signal-to-noise. (For interpre-
of this article.)
non-traumatic neuropathy: A large prospective case-control study in
Table 3
Demographic, clinical, and diagnostic features of neurological patients potentially associated with HEV infection.
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Demographic characteristics
Age,y 46 42 87 42 27 71
Sex F F M M M M
Liver function test
Alanine aminotransferase (ALT), 5–40 U/L 76 30.1 11.3 18.1 142.6 28
Aspartate aminotransferase (AST), 8–40
U/L
54 29.3 17.9 23.3 47 20
γ-glutamyltranspep-
tidase (GGT), 3-50 U/L
37 51.2 38.2 56.8 88.5 17
Alkaline phosphatase (ALP), 40–110 U/L NT 88.3 74.5 93.5 78.3 NT
Total bilirubin (TBIL), 1.71–17.1 μmol/L 9.6 6.68 24.07 23.69 7.32 28.6
Serum tumor/inﬂammation makers
Carbohydrate antigen (CA) 19–9, 0–37
U/ml
NT 4.45 NT NT NT 0.732
CA-125, 0–35 U/ml 16.7 11.55 NT NT NT 14.91
CY-211, 0–3.3 U/ml NT 3.17 NT NT NT 1.93
CA72–4, 0–8.2 U/ml 0.673 7.78 NT NT NT 1.24
CA15–3, 0–25 U/ml NT 6.69 NT NT NT NT
Neuronspeciﬁc enolase (NSE), 0–17
ng/ml
10.03 9.63 NT NT NT 7.36
C reactive protein (CRP),
≤10 mg/L
40.7 NT NT NT 1.96 NT
Viral serological testing
Hepatitis B virus surface antigen (HBsAg) − NT NT − − NT
Hepatitis B virus surface antibody
(HBsAb)
+ NT NT − − NT
HBeAg − NT NT − − NT
HBeAb − NT NT − − NT
Hepatitis B core antibody (HBcAb) + NT NT − − NT
Hepatitis C virus (HCV) − NT NT − − NT
Anti-HEV IgM S/N ratio 6.1 1.39 1.57 3.07 1.41 1.42
Anti-HEV IgG S/N ratio 9.01 4.25 3.53 2.83 3.28 1.37
Human immunodeﬁciency virus [HIV(1
+ 2)]
− NT NT − − NT
Treponema pallidum antibodies (TPAB) − NT NT − − NT
Toxoplasma (Tox)-IgM − − − − − −
Tox-IgG − − − − − −
Cytomegalovirus (CMV)- IgM − − − − − −
CMV-IgG + + + + + +
Herpes simplex virus (HSV)-IgM −
−
−
−
−
−
−
−
−
−
−
−
HSV-IgG + + + + + +
Rubella virus (RV)-IgM + + − + + −
RV-IgG + + + − + +
Cerebrospinal ﬂuid (CSF) testing
CSF protein (CSF-PR), 0.15–0.45 g/L 0.2 NT NT NT 0.36 1.11
CSF-Cl, 120–132 mmol/L 125.9 NT NT NT 125.7 123.1
CSF-GLU, 2.5–4.5 mmol /L 4.49 NT NT NT 4.41 5.32
CSF-karyocyte count, (0–8) × 106 /L 12 NT NT NT 12 23
C-TMD transparent NT NT NT transparent transparent
C-Pandy − NT NT NT − +
Immune status and past medical history
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Table 4
Seroprevalence of IgG in patients of different types of acute neurological event.
Anti-HEV IgG
+ (n= 439)
Anti-HEV
IgG-(n= 672)
t χ2 P
Age,years 64 ± 14 63 ± 15 3.94 b0.001
Sex
Male 60.82% 52.83% 6.88 0.009
Female 39.18% 47.17%
Ischemia stroke 59.68% 55.21% 2.167 0.141
Hemorrhagic stroke 12.30% 12.80% 0.060 0.807
Neurodegenerative
disease
13.44% 15.48% 0.880 0.348
Central nervous system
infections
2.96% 4.02% 0.854 0.355
Others 11.62% 12.50% 0.194 0.660
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treatment with ceftazidime.
3.4. Seroprevalence of past HEV infection
In the rest of patients without acute HEV infection, anti-HEV IgG an-
tibodies were found in 439 (39.51%) patients, compared with 522
(35.63%) healthy controls (P b 0.001) (Fig. 1 and Table 2). After
adjustment for age and sex, there was no difference of anti-HEV IgG se-
roprevalence between patients and controls (Table 2). S/N ratio of pos-
itive anti-HEV IgG was similar in the two groups (Fig. 2). Anti-HEV IgG
positivitywasmore frequent inmale and elderly in both groups, but un-
related to the incidence of any non-traumatic neurological illness
(Table 4, S1), hospital stay or treatment outcome, except linking to bet-
ter outcome of hemorrhagic stroke disease (Table 5).
4. Discussion
The current study is theﬁrst large case-control cohort study to inves-
tigate the association of HEV infection with acute non-traumaticTable 5
Hospital stay and therapeutic outcomes of neurological injury patients with detectable
versus undetectable anti-HEV IgGa .
Type of neurological event Anti-HEV
IgG+N (%)
Anti-HEV
IgG-N (%)
P
Ischemia stroke 262 371
Recovery/improvement 249 (95.04%) 350 (94.34%) 0.407
Treatment failure 1 (0.38%) 0 (0%)
Others 12 (4.58%) 21 (5.66%)
Hospital stay (average, d) 10.69 10.75 0.935
Hemorrhagic strokeb 54 86
Recovery/improvement 52 (96.30%) 72 (83.72%) 0.023
Others 2 (3.70%) 14 (16.28%)
Hospital stay (median, d) 14 (10–29) 14 (7.75–25) 0.451
Neurodegenerative diseaseb 59 104
Recovery/improvement 58 (98.31%) 100 (96.15%) 0.44
Others 1 (1.69%) 4 (3.85%)
Hospital stay (average, d) 10.31 9.18 0.376
CNS infectionsb 13 27
Recovery/improvement 13 (100%) 26 (96.30%) 1
Others 0 (0%) 1 (3.70%)
Hospital stay (median, d) 15 (9.5–25.5) 14 (8–19) 0.470
Others 51 84
Recovery/improvement 46 (90.20%) 76 (90.48%) 0.854
Treatment failure 0 (0%) 1 (1.19%)
Others 5 (9.80%) 7 (8.33%)
Hospital stay (average, d) 9.94 13.02 0.114
a Student t-test for normally distributed continuous variables whereas other continu-
ous variables were expressed inmedian (interquartile range [IQR]); the datawith skewed
distribution were compared using the Mann-Whitney U test; Chi-squared or the Fisher's
exact test for categorical variables with excepted cell sizes less than ﬁve were used.
b There is no treatment failure patient in both anti-HEV IgG positive and negative
cohorts.
non-traumatic neuropathy: A large prospective case-control study in
8 Y. Wang et al. / EBioMedicine xxx (xxxx) xxx–xxxneurological diseases in China, where GT4 HEV is predominant. We
showed that six of 1117 (0.54%) non-traumatic neuropathy injury pa-
tients and ten of 1475 (0.68%) controls had HEV infection (P=0.651).
This result is in contrast to all the cohort studies performed in Europe
that the prevalence of HEV viraemia in neurological patients are at
least 10 times higher than that documented in local blood donors
[8–10]. Of note, in the present study, HEV viraemia was observed in all
patients and controls who had positive anti-HEV IgM antibodies. The 6
patients had no jaundice and only two presented mildly elevated ALT.
In the past decade, HEV associated neurological syndromes have
been described in developing and developed countries, most of which
are related to GT3 or GT1 HEV [6]. The discrepancy between our study
and the European studies is likely due to the genotype differences. De-
spite an outbreak of 1989 was cause by GT1 HEV in Xinjiang province,
China, the predominant circulating genotype in China has shifted to-
wards GT4 over the decades, with occasional GT1 cases [16–20]. Several
sporadic cases of neurological injury that possibly linked to HEV infec-
tion have been documented in China [12,21–23]. However, these cases
were either coinfected with other pathogens, such as hepatitis B virus
and cytomegalovirus [21], or only positive for anti-HEV IgM
[12,22,23]. Although therewas one case of GT4 HEV related bilateral pe-
ripheral facial palsy reported in Japan [24], the causation with HEV in-
fection is uncertain. Moreover, a small cohort study performed in
China composed of 64 GBS patients and 21 encephalitis patients found
one patient with possible acute HEV infection (only anti-HEV IgM was
positive) and none of the encephalitis patients tested positive for anti-
HEV IgM, and noHEV RNAwas detected in serumand CSF [12]. Interest-
ingly, a very recent Chinese study indicated that HEV viraemia was de-
tected in 2.1% (4/188) MG patients and the all isolates were GT4 HEV
[13]. Further studies are required to clarify the causality of GT4 HEV in-
fection in neurological diseases.
GBS and NA have been identiﬁed as the most frequent HEV associ-
ated neurological disorders. Two previous reports conducted in the
Netherlands and Bangladesh,where GT3 and GT1HEV predominate, re-
spectively, revealed that 5% and 11% of GBS patients had positive anti-
HEV IgM [7,8]. More recently, a study conducted in Belgium found
that 8% of the GBS cases were possibly associated with a recent HEV in-
fection [25]. However, no conﬁrmed GBS or NA attributing to GT4 HEV
has been documented among the approximately 70 HEV-related GBS
or NA cases [6]. In our study, one of the three GBS cases appeared to
be associated with GT4 HEV. Nevertheless, the causal relationship re-
mains to be established with larger GBS population.
The rates of anti-HEV IgM positivity and HEV viraemia showed no
signiﬁcant difference between the patients and controls. However,
whether HEV is an etiology of the six non-traumatic neuropathy injury
patients reported in the present study requires further investigation.
The striking observation is that two of the 26 patientswith viral enceph-
alitis tested positive for HEV, and only these two patients among all pa-
tients with HEV showed abnormal LFTs. This is consistent with other
studies involving GT3 HEV-associated encephalitis, in which the only
two documented cases showed elevated ALT [26,27]. This observation
indicates that viral encephalitis, unlike other HEV-related neurological
illnesses, appears to present symptomatic acute hepatitis. Encephali-
tis/myelitis is one of the most common HEV-associated neurological
disorders after GBS and NA, but all had conformed GT3 HEV infections.
Recently, an experimental study in gerbils conﬁrmed that HEV can
break through the blood-brain barrier and replicate in the central ner-
vous system [28]. However, one cohort study performed in China en-
rolled 21 patients with encephalitis found no positive anti-HEV IgM or
detectable HEV RNA in the serum or CSF [12], probably because of geo-
graphical heterogeneity or small size of cohort. The present large cohort
study indicated a causal relationship between HEV and viral
encephalitis.
Patient 2 presented with a 2-month history of numbness in the left
upper extremities and was diagnosed with peripheral neuropathy. She
was positive for both anti-HEV IgM and IgG. The numbness of the leftPlease cite this article as: Wang Y, et al, Hepatitis E virus infection in acute
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negative conversation, suggesting a potential causal association. In a
previous study, viral status was shown to be associated with peripheral
neuropathy in two cases of chronic HEV infection. In one case, neurolog-
ical symptoms completely resolved,with successfulHEV clearance, after
treatment with a combination of Peg-IFN alpha and ribavirin [29]. In
contrast, the other case, who failed to achieve viral clearance by Peg-
IFN alpha treatment and reduction of immunosuppressants, had no im-
provement in symptoms and ultimately dying [30].
The relationship between HEV and ischemic neuropathy remains
less clear. In our study, involving 635 patients with posterior circulation
ischemia (PCI)/transient ischemic attack (TIA)/vertebrobasilar insufﬁ-
ciency (VBI)/stroke, two patients showed evidence of HEV infection.
Similar cases were reported in a recent study, whereby four of 238 pa-
tients who suffered stroke/TIA presented positive HEV IgM and two of
them had HEV viraemia [9]. The rate of HEV infection in ischemic neu-
ropathy patients was even lower than that in the healthy population
in the current study. There is no evidence to support a causal relation-
ship between HEV and this neurological pattern.
Of note, HEV viraemia was observed in all the patients and controls
who had positive anti-HEV IgM antibodies, amongwhich only one sam-
plewas successful sequenced.We found the viral loads inmost of the 16
samples were close to the detection threshold and the sample of suc-
cessful sequencing had the highest viral load. Thus, the failure in se-
quencing of the other 15 HEV viraemic individuals is likely due to low
viral load. The kit for HEV RNA detection used in the study is highly sen-
sitive and speciﬁc [31,32] with detection limit of 1.42 × 103 copies/mL,
which explains the high rate of HEV RNA detection and the low rate of
successful sequencing.
Since N70 neurological conditions were included in the current
study, it could be argued that the heterogeneity of the studied popula-
tion may lead to involvement of potential confounding factors, which
probably contribute to no more detected HEV infections in the cases
group as compared to the controlled one. However, as an exploratory
study, we incipiently desired to know the full range and frequency of
GT4HEV-associated neurological injury, in addition to foregoneHEV as-
sociated neurological syndromes, just as an pilot Europe study reported
in 2017 that explored the role of HEV in awide range of neurological pa-
thologies of various aetiologies [9]. The provisional ﬁndings in our study
have provided a hint of like or unlike causality between speciﬁc neuro-
logical conditions and HEV infection. Nevertheless, further studies fo-
cusing on the deﬁned neurological populations that HEV is likely a
contributor are deserved in China to precisely address the relationship
between GT4 HEV infection and speciﬁc neurological disorders.
Besides the lacking of the deﬁnite conﬁrmation of HEV genotype for
all the patients and heterogeneity of the studied population, there are
some other limitations in our current study. First, the sex and age
were not well-matched between the patient and control groups. Sec-
ondly, CSF samples were not collected for HEV RNA tests, thus lacking
of a direct proof in some patients. Thirdly, the follow-updata of HEV sta-
tus inmost cases weremissed, leading to a questionwhether the allevi-
ation of symptoms is the result from recovery of HEV infection.
In conclusion, this is the ﬁrst large cohort study of HEV infection in a
wide spectrum of neurological diseases in China, where GT4 is preva-
lent. We have demonstrated that 0.54% patients with acute non-
traumatic neurological injury had HEV infection. The overall incidence
of HEV infection was not signiﬁcantly different between patients and
healthy controls. Nevertheless, we cannot exclude a possible causative
role, suggesting that testing HEV in this population, especially in situa-
tions of unexplained deregulated liver function would be warranted.
Multicenter studies are warranted to further clarify the role of HEV in-
fection in neurological diseases in GT4 prevalent regions.
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